门诊患者处方模式与多重药物基因组检测的潜在价值
该研究采用竞争风险分析估计成人医学门诊患者5年内接受药物基因组(PGx)相关药物的累积发生率。结果显示,接受任何新PGx药物、有指南的PGx药物及有严重临床效应的PGx药物的5年累积发生率分别为42.6%、37.3%和13.7%,且在年龄>40岁、马来裔和印度裔、来自感染科/精神科/肾内科/风湿免疫科以及基线处方≥5种药物的患者中更高。
要点
- 成人医学门诊患者5年内接受任何新PGx药物的累积发生率为42.6%。
- 有指南支持及有严重临床效应的PGx药物5年累积发生率分别为37.3%和13.7%。
- 年龄>40岁、特定种族、专科及多重用药患者接受PGx药物的概率更高。
核心结论
- 医学门诊患者从先发PGx检测中获益的概率较高,且在特定亚组中更高。
研究设计与样本
- 基于成人医学门诊患者的处方模式分析,采用竞争风险分析估计5年累积发生率,并用Gray检验比较患者特征差异。
主要发现
- 接受任何新PGx药物、有指南的PGx药物及有严重临床效应的PGx药物的5年累积发生率分别为42.6%、37.3%和13.7%。
- 年龄>40岁患者接受任何新PGx药物的5年累积发生率为43.6%,高于≤40岁患者的36.0%(P < 2.2 × 10-22)。
- 马来裔和印度裔患者接受任何新PGx药物的5年累积发生率分别为50.3%和49.8%,高于华裔的31.1%(P < 2.2 × 10-22)。
- 感染科、精神科、肾内科及风湿免疫科就诊者接受任何新PGx药物的5年累积发生率分别为46.2%、48.3%、49.8%和54.8%,均高于其他专科(P值分别为2.9 × 10-4、7.4 × 10-13、< 2.2 × 10-22、< 2.2 × 10-22)。
- 基线处方≥5种药物者接受任何新PGx药物的5年累积发生率为51.7%,高于0-4种药物者的41.7%(P < 2.2 × 10-22)。
临床怎么用
- 可优先考虑对年龄>40岁、特定种族、来自感染科/精神科/肾内科/风湿免疫科及多重用药的门诊患者进行先发PGx检测评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-emptive pharmacogenomic (PGx) testing is potentially an efficient approach to improve drug safety and efficacy but the target population to test is unclear. OBJECTIVES: We aim to describe the prescription pattern of PGx drugs among adult medical outpatients. METHODS: We estimated the 5-year cumulative incidence (CI) for receiving three groups of PGx drugs using competing risks analysis: (i) all PGx drugs, (ii) PGx drugs with guidelines and (iii) PGx drugs with serious clinical effects. Comparisons of CIs were also done by patient characteristics using Gray's test. RESULTS: The 5-year CIs of receiving any new PGx drug, PGx drug with guidelines and serious clinical effects were 42.6%, 37.3% and 13.7%, respectively. The 5-year CI of receiving any new PGx drug was higher for patients >40 years old (43.6% vs ≤40 years old 36.0%, P < 2.2 × 10-22 ), Malays and Indians (50.3% and 49.8% vs Chinese 31.1%, P < 2.2 × 10-22 ), those who attended one of the following four specialties at the index visit compared to other specialties (infectious diseases [46.2% vs 42.6%, P = 2.9 × 10-4 ], psychiatry [48.3% vs 42.3%, P = 7.4 × 10-13 ], renal [49.8% vs 40.9%, P < 2.2 × 10-22 ], and rheumatology and immunology [54.8% vs 41.7%, P < 2.2 × 10-22 ]) and those prescribed ≥5 drugs at index visit (51.7% vs 0-4 drugs 41.7%, P < 2.2 × 10-22 ). CONCLUSIONS: Medical outpatients have a substantial probability of benefiting from pre-emptive PGx testing and this is higher in certain subgroups of patients.
引用
- Chan SL, Liew HZW, Nguyen F, et al. Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing. Br J Clin Pharmacol. 2020. PMID: 32559336. doi:10.1111/bcp.14439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。